ArticlePractical laboratory medicine2021
A low-cost initiative to reduce duplicate hepatitis B virus serological testing.
Article in Practical laboratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently, multiple clinical laboratories provide serological testing for hepatitis B virus (HBV) in Alberta, Canada. Concerns were raised regarding single serology specimens having duplicate testing performed during the specimen referral process from one laboratory to another. In an attempt to reduce duplicate testing for anti-HBs and HBsAg markers, we implemented a stamp on paper requisitions to identify if testing had already been performed on referred specimens. We aimed to determine the number of duplicate tests and cost of duplicate testing pre- and post-stamp implementation. STUDY
designThe requisition stamp was implemented between May and August 2016. HBV serology testing results from two clinical laboratories between January 01, 2015 and December 31, 2017 (n = 803,637) were examined. The number of tests performed on the same individual within a 3-day window was identified and the associated costs were determined.
resultsAfter stamp implementation, duplicated HBsAg and anti-HBs tests decreased from 20.8% (n = 28,545) and 18.4% (n = 20,151) to 3.7% (n = 4,604) and 2.5% (n = 2,593), respectively. This represented an estimated annual savings of $86,427 and $82,522 CAD in supply costs for HBsAg and anti-HBs tests, respectively.
conclusionsThe requisition stamp initiative was effective in reducing the number of duplicate tests performed between two laboratory sites. This low-cost intervention could be applied to other testing situations, including other highly duplicated serological markers, which may have broad reaching cost-saving effects for laboratory testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.